

32692 Customer Number PATENT PACKET No.:58232US004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

KEITH B. GORDEN, XIAOHONG QUI and JOHN P. VASILAKOS

Serial No.: Filed: 10/777,310 February 12, 2004

·

For: METHODS AND

COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-

LIKE RECEPTOR 8

Group Art Unit: 1615

Examiner:

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. Copies of any cited foreign patents, non-patent literature, and unpublished US application documents are enclosed. Pursuant to the waiver in the Pre-OG Notice, dated July 25, 2003, copies of US patents and published US patent applications are no longer required and are not enclosed. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

Should a First Office Action on the merits be mailed prior to the filing of this Disclosure Statement, please charge the requisite \$180.00 fee (pursuant to 37 C.F.R. §§ 1.97(c) and 1.17(p)) to Deposit Account No. 13-3723.

08/17/2004 EAREGAY1 00000015 133723 10777310

01 FC:1806 180.00 DA

HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITE.
WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL
WAN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS
P.O. BOX 1450

ALEXANDRIA YA 22313.1450 ON 12. 2014

PURNED ON SUR X. Harriser

Applicants submit that the above references, whether taken alone or in combination with each other neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to the captioned application is respectfully requested.

Respectfully submitted,

CHRISTOPHER D. GRAM Registration No. 43,643 Attorney for Applicants

CDG:jlh/58232US004IDS Office of Intellectual Property Counsel 3M Innovative Properties Company P.O. Box 33427 St. Paul, Minnesota 55133-3427 (651) 733-1507 Facsimile: (651) 736-3833

Dated: August 12, 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use grammany sheets as necessary) AUG 1 6 2004 Page 1 of 5

٦	Application Number	10/777,310	
1	Filing Date	February 12, 2004	
	In re Application of:	Keith B. Gorden, Xiaohong Qui and John P. Vasilakos	
	Art Unit	1615	
	Examiner Name	Unknown	
	Attorney Case Number	58232US004	

			U.S. Patent	Documents	Pages, Columns, Lines, Where
xam.	Cite	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Pessages or Relevant Figures Appear
Init.*	No.	Doc. Number-(Kind Code if Known)	08-25-1987	Gerster	
	A1	US- 4,689,338	10-06-1987	Gerster	
	A2	US- 4,698,348	05-29-1990	Gerster et al.	
	A3	US- 4,929,624	01-29-1991	Andre et al.	
	A4	US- 4,988,815	08-06-1991	Gerster	
	A5	US- 5,037,986	12-29-1992	Gerster	
	A6	US- 5,175,296		Wick et al.	
	A7	US- 5,238,944	08-24-1993	Gerster et al.	
	A8	US- 5,266,575	11-30-1993		
	A9	US- 5,268,376	12-07-1993	Gerster	
	A10	US- 5,346,905	09-13-1994	Gerster	-
	A11	US- 5,352,784	10-04-1994	Nikolaides et al.	
	A12	US- 5,367,076	11-22-1994	Gerster	
	A13	US- 5,376,501	12-27-1994	Mariën et al.	
	A14	US- 5,389,640	02-14-1995	Gerster et al.	
_	A15	US- 5,395,937	03-07-1995	Nikolaides et al.	
-	A16	US- 5,446,153	08-29-1995	Lindstrom et al.	
	A17	US- 5,482,936	01-09-1996	Lindstrom	
	A18		02-27-1996	Lindstrom et al.	
├─	A19		06-11-1996	Gerster	
-	A20		02-25-1997	Gerster et al.	
-	A21		12-02-1997	Lindstrom	
-	A22		04-21-1998	Gerster et al.	
-	A23		05-26-1998	Gerster	
-	A24		08-17-1999	Beaurline et al.	
-			02-22-2000	Hirota et al.	
1	A2	+	03-21-2000	Tomai et al.	
-	A2		05-30-2000	Nanba et al.	
1	A2		07-04-2000	Miller et al.	
1	A2		08-29-2000		
I	A2	9 US- 6,110,929	00 20 2000		

*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 2 of 5

Application Number	10/777,310
Filing Date	February 12, 2004
In re Application of:	Keith B. Gorden, Xiaohong Qui and John P. Vasilakos
Art Unit	1615
Examiner Name	Unknown
Attorney Case Number	58232US004
	58232US004

			U.S. Patent	Documents	Pages, Columns, Lines, Where
Exam.	Cite	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
Init.*	No.	Doc. Number-(Kind Code if Known)	09-05-2000	Johnson et al.	
	A30	US- 6,113,918	-	Krieg et al.	
	A31	US- 6,194,388 B1	02-27-2001	Gerster et al.	
	A32	US- 6,194,425 B1	02-27-2001	Tomai et al.	
	A33	US- 6,200,592 B1	03-13-2001		
	A34	US- 6,207,646 B1	03-27-2001	Krieg et al.	
	A35	US- 6,239,116 B1	05-29-2001	Krieg et al.	
	A36	US- 6,245,776 B1	06-12-2001	Skwierczynski et al.	
	A37	US- 6,303,347 B1	10-16-2001	Johnson et al.	
	A38	US- 6,323,200 B1	11-27-2001	Gerster et al.	
	A39	US- 6,329,381 B1	12-11-2001	Kurimoto et al.	
_	A40	US- 6,331,539 B1	12-18-2001	Crooks et al.	
	A41	US- 6,339,068 B1	01-15-2002	Krieg et al.	
	A42	US- 6,376,501 B1	04-23-2002	Isobe et al.	
-	A43	US- 6,376,669 B1	04-23-2002	Rice et al.	
\vdash	A44	US- 6,387,938 B1	05-14-2002	Mizuguchi et al.	
-	A45	US- 6,406,705 B1	06-18-2002	Davis et al.	
┢	A46	US- 6,426,334 B1	07-30-2002	Agrawal et al.	
\vdash	A47	US- 6,440,992 B1	08-27-2002	Gerster et al.	
-	A48		11-05-2002	Agrawal	
H	A49		09-17-2002	Coleman et al.	
-	A50		02-04-2003	Gerster et al.	
-	A51		02-11-2003	Kato et al.	
\vdash	A52		02-11-2003	Gerster et al.	
\vdash	A53		02-25-2003	Johnson et al.	
-	A54		02-25-2003	Dellaria et al.	
1	A5	-	04-01-2003	Crooks et al.	
-	A5		04-08-2003	Dellaria et al.	
1	A5		04-08-2003	Dellaria et al.	
-	A5		05-06-2003	Tomai et al.	

*Examiner:	Date Considered:	
EXAMINER: Initial if reference considered, whether or conformance and not considered. Include copy of this	not citation is in conformance with MPEP 609. Dra form with next communication to applicant.	w line through citation if not in
conformance and not considered; include eap,	01.1	PTO 1449 (Modified

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 3 of 5

-	
Application Number	10/777,310
Filing Date	February 12, 2004
In re Application of:	Keith B. Gorden, Xiaohong Qui and John P. Vasilakos
Art Unit	1615
Examiner Name	Unknown
Attorney Case Number	58232US004

			U.S. Patent I	Documents	Pages, Columns, Lines, Where
Exam.	Cite	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
Init.*	No.	Doc. Number-(Kind Code if Known)	06-03-2003	Crooks et al.	
	A59	US- 6,573,273 B1	11-18-2003	Johnson	
	A60	US- 6,649,172 B2	12-02-2003	Crooks et al.	
	A61	US- 6,656,938 B2	12-02-2003	Crooks et al.	
	A62	US- 6,660,735 B2	12-09-2003	Crooks et al.	
	A63	US- 6,660,747 B2		Charles et al.	
A64		US- 6,664,260 B2	12-16-2003	Dellaria et al.	
	A65	US- 6,664,264 B2	12-16-2003	Crooks et al.	
	A66	US- 6,664,265 B2	12-16-2003	Bonk et al.	
	A67	US- 6,667,312 B2	12-23-2003		
	A68	US- 6,670,372 B2	12-30-2003	Charles et al.	
	A69	US- 6,677,347 B2	01-13-2004	Crooks et al.	
	A70	US- 6,677,348 B2	01-13-2004	Heppner et al.	
_	A71	US- 6,677,349 B1	01-13-2004	Griesgraber	
\vdash	A72	US- 6,683,088 B2	01-27-2004	Crooks et al.	_
\vdash	A73	US- 2002/0016332 A1	02-07-2002	Slade	
H	A74	US- 2002/0055517 A1	05-09-2002	Smith	
\vdash	A75	US- 2002/0058674 A1	05-16-2002	Hedenstrom et al.	
\vdash	A76	US- 2002/0110840 A1	08-15-2002	Tomai et al.	
\vdash	A77	US- 2003/0133913 A1	07-17-2003	Tomai et al.	
A78		US- 2003/0139364 A1	07-24-2003	Krieg et al.	
1	A79	US- 2003/0144283 A1	07-31-2003	Coleman et al.	
-	A80		10-23-2003	Averett et al.	
1	A8		01-22-04	Gorden et al.	
1	A8	1.000,0007.04	01-15-2004	Dellaria et al.	

1	1402 I	00- 200	470010001							
==	Foreign Patent Documents									
Exam.	Cite	Fore	eign Patent Document	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)				
Init.*	No.	Ctry. Code	Number-KindCode (If known)	MM-DD-YYYY		Of Ticherent Service	Y			
H	B1	EP	0 394 026	10-24-1990			×			
	B2	EP	1 104 764 A1 /	06-06-2001			<u></u>			

	Date Considered:					
*Examiner:	is in conformance with MPEP 609. Draw line through citation if not in					
*Examiner: EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citat conformance and not considered. Include copy of this form with next communication to applicant.						
conformance and not considered. Include copy of this form that	itto (it-dified)					

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 4 of 5

Application Number	10/777,310		
Filing Date	February 12, 2004		
In re Application of:	Keith B. Gorden, Xiaohong Qui and John P. Vasilakos		
Art Unit	1615		
Examiner Name	Unknown		
Attorney Case Number	58232US004		

			Fo	reign Patent I	Jocuments	Pages, Columns, Lines,	
Exam. Cite		Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	(Check if yes)
Init.*	No.	Ctry. Code	Number-KindCode (If known)				
	В3	JР	9-208584	08-12-1997			×
	B4	JP	11-80156	03-26-1999	(translation only)		×
	B5	JP	11-222432	08-17-1999			X
	В6	JP	2000-247884 (abstract only)	09-12-2000	0		×
	B7	wo	00/47719 A2	08-17-2000			X
	B8	wo	00/75304 A1	12-14-2000			\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
<u> </u>	B9	wo	00/76505 A1	12-21-2000			+ ^
	B10	wo	00/76518A1	12-21-2000			+ ^
	B11	wo	01/74343 A2	10-11-2001			+ <u>*</u>
-	B12	wo	02/36592 A1 .	05-10-2002			1 ×
	B13	wo	02/46188 A2	06-13-2002			\ \ \ \ \ \
\vdash	B14	wo	.02/46189 A2	06-13-2002			^
\vdash	B15		02/46190 A2	06-13-2002			+ ^
\vdash	B16	wo	02/46191 A2	06-13-2002	!		+ ^
<u> </u>	B17	wo	02/46192 A2	06-13-2002	2		$\frac{\hat{x}}{x}$
-	B18	wo	02/46193 A2	06-13-2002	2		$\frac{1}{x}$
H-	B19	wo	02/46194 A2	06-13-2002	2		$+\hat{x}$
\vdash	B20	wo	02/46749 A2	06-13-200	2		 ^
\vdash	B2	ı wo	02/085905 A1	10-31-200	2		×
\vdash	B2:	2 WO	02/102377 A1	12-27-200	2		$+\hat{x}$
	B2	3 WO	03/020889 A2	03-13-200	3		$\frac{}{x}$
-	B2	4 WO	03/043572 A2	05-30-200	3		$\frac{}{x}$
	B2	5 WO	03/045391 A1	06-05-200	3		$+\hat{x}$
-	B2	6 WO	03/103584 A2	12-18-200)3		

	B24	wo	03/043572 A2	05-30-2003		- V
	B25	wo:	03/045391 A1	06-05-2003		
	B26	wo	03/103584 A2	12-18-2003		^
Exam.	Cite	OTH	ER DOCUMENTS (In			
Init.*	Exam. Cite Include name of the author (in CAPITAL LETTERS), tills of the article (when appropriate), test of the author (in CAPITAL LETTERS), tills of the article (when appropriate), to the law in the article (when appropriate), and the article (when appropriate), article (
		or Leuk	ocyte biology, volume			

<u></u>	
*Examiner:	Date Considered:
	whether or not citation is in conformance with MPEP 609. Draw line through citation if not in ppy of this form with next communication to applicant.
conformance and not considered. Include of	ppy of this form with next continuous to approximately the second

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 5 of 5

Application Number	10/777,310
Filing Date	February 12, 2004
In re Application of:	Keith B. Gorden, Xiaohong Qui and John P. Vasilakos
Art Unit	1615
Examiner Name	Unknown
Attorney Case Number	58232US004

		Destinant Papers etc.)		
OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)				
Exam.	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the term (cook, inagazine, points), solution include nam		
Init.*	C2	Ol list at al "Development of a Topically Active Imiquimod Formulation", Pharmaceutical		
3.		Development and Technology, 4(1), pp 35-43 (1999)		
	C3	Development and Techniquay, "(1), pp. 60 - (1). Brassard et al.; "Interferon-a as an immunotherapeutic protein"; Journal of Leukocyte Biology; Vol. 71; April 2002; pgs. 565-581		
	C4	Izumi et al.; "1H-imidazo[4,5-c]quinoline Derivatives as Novel Potent I Nr-G Suppressors. Synthesis and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substitute 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substitute 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substitute 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substitute 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substitute 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substitute 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substitute 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship of 1-, 2-and 4-Substitute 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship or 1-, 2-and 4-Substitute 1H-imidazo[4,5-c]quinolines or 1H-and Structure-Activity Relationship or 1-, 2-and 4-Substitute 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]quinolines		
-	C5	Human Peripheral Blood Mononuclean Cells and Ostrobusty 5		
\vdash	C6	Hemmi et al., "Small anti-viral compounds activate immune cells via the TER7 MyDeo-dependent Hemmi et al., "Small anti-viral compounds activate immune cells via the TER7 MyDeo-dependent immune cells		
	C7	Medzhitov, "Toll-Like Receptors and Innate Immunity", Nature Reviews Immuniogy, Vol. 1,		
	C8	Jurk et al. "Human TLR7 and TLR8 independently confer responsiveness to the antivitial compound		
-	C9	Akira et al., "Toll-like receptors: critical proteins linking innate and acquired intributily, News.		
T.	C10	The standard compounds activate immune cells via TER7 and TER8,		

*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.